Palisade Bio, INC DEF 14A proxy statements

Palisade Bio, Inc. has announced its 2026 Annual Meeting of Stockholders will be held virtually on June 10, 2026, to vote on key proposals including director elections and equity plan approvals.

Palisade Bio, Inc. filed a supplement to its proxy statement, correcting the number of outstanding common shares for its upcoming Special Meeting due to recent warrant exercises.

Palisade Bio, Inc. calls a Special Meeting for December 3, 2025, to vote on issuing shares for warrants and increasing authorized common stock.

Palisade Bio, Inc. is urgently soliciting stockholder votes for its upcoming Annual Meeting on October 17, 2025, emphasizing the need for active participation.

Palisade Bio, Inc. has filed a definitive proxy statement with the SEC, signaling an upcoming shareholder meeting.

Palisade Bio, Inc. will hold its 2025 Annual Meeting to vote on director elections, auditor ratification, and a reverse stock split to regain Nasdaq compliance.

Palisade Bio, Inc. is seeking stockholder approval for the issuance of up to 8.6 million common shares underlying new warrants, a move crucial for potential funding and operational continuity.

Palisade Bio, Inc. has filed a definitive proxy statement with the SEC.

Palisade Bio announces its 2024 Annual Meeting of Stockholders to be held virtually on July 8, 2024, featuring proposals for director elections and auditor ratification.